Title: 18501 Twenty patients with moderate to severe psoriasis succesfully treated with brodalumab after a failed treatment with secukinumab
Abstract: Psoriasis is a chronic inflammatory skin disease, associated with a range of co-morbidities, including metabolic and psychological disorders. Brodalumab is a human monoclonal antibody that antagonizes the interleukin (IL) 17 pathway by binding to human IL-17RA. The mechanism of action of brodalumab is unique because it inhibits the IL-17 receptor and not the IL-17A molecule itself like secukinumab and ixekizumab. IL-17RA binds IL-17A, IL-17C, IL17F, and IL-25 and is expressed in multiple tissues like vascular endothelial cells, peripheral T cells, B-cell lineages, fibroblasts, etc. We present 20 patients with moderate to severe psoriasis successfully treated with brodalumab after a failed treatment with secukinumab (16 patients with plaque psoriasis and 4 with palmoplantar pustulosis). Twelve of them had received secukinumab as first line therapy, whereas the rest had undergone of through at least one biologic therapy in the past. All patients had not achieved PASI-75 or PPPGA:0/1 after 12 weeks of therapy, so we switched to brodalumab. Results showed PASI-90, PASI-100, and PPPGA:0 scores in 20% and 80% and 100% of the patients respectively whereas 100% of patients had achieved sPGA 0 or 1 in week 12 of therapy with brodalumab. Brodalumab was more effective than secukinumab in the above patients. Is unknown how patients, who have failed treatment with anti–IL-17 agent respond to brodalumab treatment, but that may relate to the unique mechanism of the drug, that targets IL-17RA. Therefore, brodalumab may be a therapeutic option for psoriasis patients, who have failed other therapies, including other IL-17 antagonists. More data are needed.
Publication Year: 2020
Publication Date: 2020-11-28
Language: en
Type: article
Indexed In: ['crossref']
Access and Citation
Cited By Count: 2
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot